drugset / Trial / NCT05333705

Donor Immune Cell Therapy for Acute Myeloid Leukemia

NCT05333705

NaSingle-groupOpen-labelTreatment

Summary

This study aims to introduce a new technology of donor NK cell infusion. NK cells defend against viruses and cancer cells in vivo whereas this effect declines in patiens with tumors. In this study, NK cells will be separated from donated peripheral blood or umbilical cord blood. Eligible NK cells will be infused to patients with Acute myeloid leukemia (AML). This new therapy will probably induce their sustained remission and reduce recurrences.

Timeline

Start
2021-07-01
Primary completion
2024-07-01
Completion
2024-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject TROCULEUCEL Cell therapy